Research Article
Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study
Table 6
Efficacy and safety of rivaroxaban in patients with PE combined with or without frailty.
| | | PE with frailty (22) | PE without frailty | | value |
| Efficacy | | | | -0.72 | 0.471 | Disappeared | 55 | 12 (54.55%) | 43 (67.19%) | 1.35 | 0.289 | Effective | 20 | 8 (36.36%) | 12 (18.75%) | 2.846 | 0.092 | No effect | 5 | 1 (4.55%) | 4 (6.25%) | <0.001 | 1 | Progressed | 2 | 0 (0.00%) | 2 (3.13%) | | 0.552 |
| Bleeding | | | | -1.363 | 0.173 | Bleeding | 39 | 8 (36.36%) | 31 (48.44%) | 0.963 | 0.326 | Mild bleeding | 27 | 13 (59.09%) | 27 (42.19%) | 1.88 | 0.170 | Serve bleeding | 1 | 0 (0.00%) | 1 (1.56%) | | 0.744 | Major bleeding | 1 | 1 (4.55%) | 0 (0.00%) | | 0.256 |
|
|